Interstitial brachytherapy for lip carcinomas : Comparison between Ir-192 low-dose-rate and high-dose-rate treatment
Copyright © 2023. Published by Elsevier Masson SAS..
PURPOSE: Low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy are known to be effective in the treatment of lip carcinomas. The aim of this study was to retrospectively compare oncologic and toxicity outcomes between the two techniques.
PATIENTS AND METHODS: From 2007 to 2018, patients at the Institut de cancérologie de Lorraine (France) who received exclusive or adjuvant interstitial brachytherapy for lip squamous carcinomas were studied. Two groups were defined: the LDR/PDR group, including patients treated with iridium-192 wires, or pulsed-dose rate technique, and the high-dose-rate group, with patients treated by high-dose-rate technique. The dose ranged between 50Gy and 65Gy (depending on previous surgery) for low-dose-/pulsed-dose rate treatments, and 39Gy for high-dose-rate (twice a day). Early, late toxicity events and oncologic control were reported.
RESULTS: Among the 61 patients whose data were analyzed retrospectively, 36 received the low-dose-/pulsed-dose rate treatment (59%) and 25 the high-dose-rate brachytherapy (41%). The median follow-up time was 44 months. At 36 months, the local control rates were 96.3% for LDR/PDR group and 100% for HDR (P=0.180). The regional control rates were 85.9% and 92% without any difference according to the two groups (P=0.179). The specific overall survival rate was 95.5% with no difference between groups. There were more grade 2 or higher mucositis in the HDR group than in LDR/PDR group (40% versus 16.7%, P=0.042). One case of grade 3 mucositis was recorded in each group. No grade 3 late complications were recorded. High-dose-rate brachytherapy reduced the length of hospitalization by 2 days (P<0.001).
CONCLUSION: High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique - 28(2024), 2 vom: 18. Apr., Seite 145-151 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cuenin, M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.04.2024 Date Revised 22.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canrad.2023.06.031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365635537 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365635537 | ||
| 003 | DE-627 | ||
| 005 | 20240422232013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canrad.2023.06.031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1383.xml |
| 035 | |a (DE-627)NLM365635537 | ||
| 035 | |a (NLM)38072744 | ||
| 035 | |a (PII)S1278-3218(23)00243-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cuenin, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interstitial brachytherapy for lip carcinomas |b Comparison between Ir-192 low-dose-rate and high-dose-rate treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.04.2024 | ||
| 500 | |a Date Revised 22.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Masson SAS. | ||
| 520 | |a PURPOSE: Low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy are known to be effective in the treatment of lip carcinomas. The aim of this study was to retrospectively compare oncologic and toxicity outcomes between the two techniques | ||
| 520 | |a PATIENTS AND METHODS: From 2007 to 2018, patients at the Institut de cancérologie de Lorraine (France) who received exclusive or adjuvant interstitial brachytherapy for lip squamous carcinomas were studied. Two groups were defined: the LDR/PDR group, including patients treated with iridium-192 wires, or pulsed-dose rate technique, and the high-dose-rate group, with patients treated by high-dose-rate technique. The dose ranged between 50Gy and 65Gy (depending on previous surgery) for low-dose-/pulsed-dose rate treatments, and 39Gy for high-dose-rate (twice a day). Early, late toxicity events and oncologic control were reported | ||
| 520 | |a RESULTS: Among the 61 patients whose data were analyzed retrospectively, 36 received the low-dose-/pulsed-dose rate treatment (59%) and 25 the high-dose-rate brachytherapy (41%). The median follow-up time was 44 months. At 36 months, the local control rates were 96.3% for LDR/PDR group and 100% for HDR (P=0.180). The regional control rates were 85.9% and 92% without any difference according to the two groups (P=0.179). The specific overall survival rate was 95.5% with no difference between groups. There were more grade 2 or higher mucositis in the HDR group than in LDR/PDR group (40% versus 16.7%, P=0.042). One case of grade 3 mucositis was recorded in each group. No grade 3 late complications were recorded. High-dose-rate brachytherapy reduced the length of hospitalization by 2 days (P<0.001) | ||
| 520 | |a CONCLUSION: High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bas débit de dose | |
| 650 | 4 | |a Brachytherapy | |
| 650 | 4 | |a Carcinome des lèvres | |
| 650 | 4 | |a Contrôle local | |
| 650 | 4 | |a Curiethérapie | |
| 650 | 4 | |a Haut débit de dose | |
| 650 | 4 | |a High-dose-rate | |
| 650 | 4 | |a Lip carcinoma | |
| 650 | 4 | |a Local control | |
| 650 | 4 | |a Low-dose-rate | |
| 650 | 7 | |a Iridium-192 |2 NLM | |
| 650 | 7 | |a Iridium Radioisotopes |2 NLM | |
| 700 | 1 | |a Salleron, J |e verfasserin |4 aut | |
| 700 | 1 | |a Peiffert, D |e verfasserin |4 aut | |
| 700 | 1 | |a Meknaci, É |e verfasserin |4 aut | |
| 700 | 1 | |a Gallet, P |e verfasserin |4 aut | |
| 700 | 1 | |a Abushama, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Py, J-F |e verfasserin |4 aut | |
| 700 | 1 | |a Renard, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique |d 1998 |g 28(2024), 2 vom: 18. Apr., Seite 145-151 |w (DE-627)NLM092193420 |x 1769-6658 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:2 |g day:18 |g month:04 |g pages:145-151 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canrad.2023.06.031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 2 |b 18 |c 04 |h 145-151 | ||